A feasibility study of total endovascular aortic arch replacement--from stent-graft design to pre-clinical testing.
A feasibility study of total endovascular aortic arch replacement--from stent-graft design to pre-clinical testing.
复制标题
全血管内主动脉弓置换术的可行性研究——从覆膜支架设计到临床前测试。
DOI:
10.1016/j.jtcvs.2015.10.092
复制
发表时间:
2016
期刊:
影响因子:
--
通讯作者:
Ren Jun
中科院分区:
文献类型:
--
作者:
Yang Jian;Liu Yang;Duan Weixun;Yi Dinghua;Yu Shiqiang;Ma Rui;Ren Jun
ObjectiveThis study aimed to evaluate the safety and feasibility of total endovascular repair of the aortic arch using a novel designed stent-graft system (Yanger stent-graft system; Lifetech Scientific, Shenzhen, China) in vitro and in a canine model.MethodsThe Yanger stent-graft system is composed of a main stent-graft, branched stent-graft, and a delivery system. In an in vitro aortic arch simulation test bench, the system was tested, and the success rate of stent-graft releasing, anchoring, and positioning was recorded and analyzed. Meanwhile, in vivo implantation of the Yanger stent-graft system was carried out in 16 healthy adult crossbreed dogs. The feasibility of using these stent-grafts was evaluated with aortography, multislice computed tomography, and autopsy 6 months after the procedure.ResultsAll stent-graft releasing and positioning were successful for in vitro test. In the canine model, the Yanger stent-graft system was placed successfully in the aortic arch in all 14 dogs with the exception of 2 mortalities. All dogs survived for at least 3 months with normal physiologic signs. Aortography, multislice computed tomography, and animal necropsy revealed good fixation in all cases. The ascending aorta, descending aorta, brachiocephalic trunk, and left subclavian artery were all covered without endoleak. There was no significant obstruction or stenosis in brachiocephalic branches at the 6-month follow-up.ConclusionsTotal endovascular repair of aortic arch with the novel designed Yanger stent-graft system is safe and feasible in preclinical studies. With a better understanding of preclinical knowledge, patient selection criteria and first-in-human studies will be addressed.